METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Clinical trials for METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could smarter dosing keep prostate cancer treatable longer?
Disease control OngoingThis study tests a new approach for men with stage IV prostate cancer that still responds to hormone therapy. Instead of continuous hormone treatment, doctors adjust the dose based on PSA levels and add chemotherapy. The goal is to see if this can keep the cancer sensitive to hor…
Matched conditions: METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Promising combo targets genetic weakness in advanced prostate cancer
Disease control OngoingThis study tests whether adding the drug niraparib to standard hormone therapy (abiraterone and prednisone) can slow cancer growth better than hormone therapy alone. It includes men with metastatic prostate cancer that has a specific genetic change (HRR gene mutation). The goal i…
Matched conditions: METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 12, 2026 13:40 UTC